SCHEMBL5553889

SCHEMBL5553889

NC(=O)c1cc2c(Nc3ccc(-c4ccccc4)cc3)cnc(-c3ccccc3)c2s1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 5/20 0.65
MAP2K1 Q02750 2/20 0.49
MAPK1 P28482 2/20 0.49
CSF1R P07333 9/20 0.46
ROCK1 Q13464 3/20 0.46
PIM1 P11309 2/20 0.46
FGFR1 P11362 2/20 0.46
PRKACA P17612 2/20 0.46
KDR P35968 2/20 0.46
FLT3 P36888 2/20 0.46
MAPK8 P45983 2/20 0.46
MAPK9 P45984 2/20 0.46
GSK3A P49840 2/20 0.46
GSK3B P49841 2/20 0.46
RPS6KA3 P51812 2/20 0.46
CDK5 Q00535 2/20 0.46
AURKB Q96GD4 2/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
PAK4 O96013 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5553787 0.89 MAP3K8 (0.65) MAP3K8MAP2K1MAPK1CSF1RROCK1
SCHEMBL5550360 0.88 MAP3K8 (0.57) MAP3K8MAP2K1MAPK1CSF1RROCK1
SCHEMBL5550658 0.88 MAP3K8 (0.64) MAP3K8MAP2K1MAPK1CSF1RROCK1
SCHEMBL5553894 0.88 MAP3K8 (0.64) MAP3K8MAP2K1MAPK1CSF1RROCK1
SCHEMBL5554216 0.83 MAP3K8 (0.60) MAP3K8MAP2K1MAPK1CSF1RROCK1
SCHEMBL5550743 0.79 MAP3K8 (1.00) MAP3K8MAP2K1MAPK1CSF1RROCK1
SCHEMBL5550740 0.78 MAP3K8 (0.63) MAP3K8MAP2K1MAPK1PIM1PRKACA
SCHEMBL5550172 0.77 MAP3K8 (0.53) MAP3K8MAP2K1MAPK1CSF1RROCK1
SCHEMBL5555801 0.76 MAP3K8 (0.59) MAP3K8MAP2K1MAPK1CSF1RROCK1
SCHEMBL5550805 0.75 MAP3K8 (0.53) MAP3K8GSK3AGSK3BAURKBPAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753428-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2007-02-21 EP disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 US disclosed
WO-2005110410-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 MAP3K8 13/4885MAP2K1 216/4885MAPK1 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.